Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Sensidose
Deal Size : $9.3 million
Deal Type : Acquisition
Navamedic ASA: Amended Cash Offer to Acquire Sensidose AB And Acquisition of Shares in Sensidose AB
Details : Through the acquisition, Navamedic will broaden its product portfolio, including Flexilev, containing two active substances, levodopa and carbidopa and to support patients suffering from medical conditions, such as Parkinson's disease.
Product Name : Flexilev
Product Type : Other Small Molecule
Upfront Cash : $9.3 million
April 24, 2023
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Sensidose
Deal Size : $9.3 million
Deal Type : Acquisition
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Sensidose
Deal Size : $7.2 million
Deal Type : Acquisition
Navamedic ASA: Recommended Cash Offer to Acquire Sensidose for Approximately SEK 75 Million
Details : Through the acquisition, Navamedic will broaden its product portfolio and to support patients suffering from medical conditions, such as Parkinson's disease, including Flexilev, containing two active substances, levodopa and carbidopa.
Product Name : Flexilev
Product Type : Other Small Molecule
Upfront Cash : $7.2 million
March 29, 2023
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Sensidose
Deal Size : $7.2 million
Deal Type : Acquisition
Lead Product(s) : Clindamycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : InfoRLife SA
Deal Size : Undisclosed
Deal Type : Agreement
Navamedic ASA Acquires Innovative Antibiotic Product for Hospital Use in The Nordic Region
Details : Clindamycin is a well-established antibiotic used in treatment of severe infections, including staphylococcal bone and joint infections, chronic sinusitis and infections of the lower respiratory tract.
Product Name : Clindamycin-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : Clindamycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : InfoRLife SA
Deal Size : Undisclosed
Deal Type : Agreement